People differ in how open-ended or limited they perceive their future. We argue that individual differences in future time perspective affect the activation of implicit motives. Perceiving the time remaining for the satisfaction of one’s motives as limited should be associated with a higher activation of these motives than perceiving one’s future as more open-ended. Given that future time perspective decreases across adulthood, older adults should score higher on implicit motives than younger adults. This hypothesis was supported in a study with young ( n = 53, age M = 25.60 years) and older adults ( n = 55, age M = 68.05 years). Additionally, an experimental manipulation of future time perspective showed that age-related differences in implicit motives are influenced by future time perspective. These findings demonstrate that future time perspective is an important factor to explain the strength of motives.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lKOBs9
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
This case report outlines the possibility of accelerated tooth movement with the combination of microosteoperforation and mini-screws. A 14-...
-
by Rebekah L. Rogers, Ling Shao, Kevin R. Thornton One common hypothesis to explain the impacts of tandem duplications is that whole gene ...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2juls25 via IFTTT
-
by Qi Quan, Lei Hong, Biao Chang, Ruoxi Liu, Yun Zhu, Jiang Peng, Qing Zhao, Shibi Lu Purpose The purpose of this study was to simulate and...
-
A critical step in cellular-trafficking pathways is the budding of membranes by protein coats, which recent experiments have demonstrated ca...
-
by Mark A. Valasek, Irene Thung, Esha Gollapalle, Alexey A. Hodkoff, Kaitlyn J. Kelly, Joel M. Baumgartner, Vera Vavinskaya, Grace Y. Lin, A...
-
The secondary channel (SC) of multisubunit RNA polymerases (RNAPs) allows access to the active site and is a nexus for the regulation of tra...
-
by Hellen Houlleberghs, Anne Goverde, Jarnick Lusseveld, Marleen Dekker, Marco J. Bruno, Fred H. Menko, Arjen R. Mensenkamp, Manon C. W. Sp...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου